EyePoint Pharmaceuticals has appointed Michael Campbell to the position of Chief Commercial Officer, strengthening its leadership ahead of anticipated clinical data for its lead candidate. Campbell brings more than three decades of commercial expertise in the ophthalmology sector, with a track record of executing successful product launches across multiple therapeutic areas.
In his new role, Campbell will direct the company's commercial strategy for DURAVYU, an investigational sustained-release treatment currently in Phase 3 development for wet age-related macular degeneration and diabetic macular edema. The appointment comes as EyePoint prepares to present topline efficacy and safety data for the program in mid-2026, a critical milestone for the biopharmaceutical company.
Campbell's previous experience includes leadership positions overseeing commercial operations for marquee retinal disease therapies, including Lucentis and Xiidra. His appointment reflects EyePoint's focus on building commercial infrastructure during the advancement of its clinical pipeline.